15 related articles for article (PubMed ID: 38478015)
1. Activation of the MEK/ERK Pathway Mediates the Inhibitory Effects of Silvestrol on Nasopharyngeal Carcinoma Cells via RAP1A, HK2, and GADD45A.
Yu LR; Han XZ; Tang YZ; Liu D; Luo XQ; Qiu XW; Feng J; Yuan WX; Ding JY
Front Biosci (Landmark Ed); 2024 Apr; 29(4):160. PubMed ID: 38682208
[TBL] [Abstract][Full Text] [Related]
2. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
[TBL] [Abstract][Full Text] [Related]
3. Exosomes derived from Taxol-resistant nasopharyngeal carcinoma (NPC) cells transferred DDX53 to NPC cells and promoted cancer resistance to Taxol.
Yuan F; Zhou ZF
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):127-138. PubMed ID: 33506900
[TBL] [Abstract][Full Text] [Related]
4. N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1.
Dong G; Yu J; Shan G; Su L; Yu N; Yang S
Front Cell Dev Biol; 2021; 9():731810. PubMed ID: 34950654
[TBL] [Abstract][Full Text] [Related]
5. Circular RNA circ_0005667 promotes cisplatin resistance of endometrial carcinoma cells by regulating IGF2BP1 through miR-145-5p.
Sun G; Tian J; Xiao Y; Zeng Y
Anticancer Drugs; 2023 Aug; 34(7):816-826. PubMed ID: 36728962
[TBL] [Abstract][Full Text] [Related]
6. IGF2BP1 enhances the stability of SIK2 mRNA through m
Xu Y; Xu L; Kong Y; Li K; Li J; Xu F; Liang S; Chen B
Biochem Biophys Res Commun; 2023 Dec; 684():149113. PubMed ID: 37866243
[TBL] [Abstract][Full Text] [Related]
7. m 6 A reader IGF2BP1 reduces the sensitivity of nasopharyngeal carcinoma cells to Taxol by upregulation of AKT2.
Zhao C; Zhang F; Tian Y; Tang B; Luo J; Zhang J
Anticancer Drugs; 2024 Jul; 35(6):501-511. PubMed ID: 38478015
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
